Management holds a CLEAR Outcomes Company update conference call on March 6 at 8 am. Webcast Link
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on ESPR:
- Esperion Tanks on Nexletol Cardiovascular Data
- Esperion to hold a conference call
- Esperion announced full results from landmark CLEAR outcomes study
- Landmark CLEAR Outcomes Study Demonstrates NEXLETOL® (bempedoic acid) Tablet is the Only LDL-C Lowering Therapy Since Statins to Reduce Hard Ischemic Events in a Broad Population of Both Primary Prevention and Secondary Prevention Patients
- Esperion reinstated with a Neutral at BofA
